2017 American Transplant Congress
IgM Immunotherapy Restores Immune Homeostasis in Type 1 Diabetes.
Goal: To determine the mechanism(s) by which IgM immunotherapy restores immune homeostasis in Type 1 Diabetes (T1D).Background: IgM immunotherapy prevents the onset and progression of…2017 American Transplant Congress
Effect of Two Anti-CD20 Abs on B Cell Depletion and Reconstitution in Non-Human Primates.
Background: B lymphocytes play a central role in host immunity, including antibody elaboration and antigen presentation, and B-cell depletion is being explored to modulate alloimmunity.…2017 American Transplant Congress
Induction of Proliferative Responses in B Cell and Plasma Cell Populations Following Proteasome Inhibitor Desensitization Treatment in Rhesus Macacques and Humans.
1U of Cincinnati, Cincinnati; 2Duke, Durham; 3Cincinnati Childrens, Cincinnati
Proteasome inhibitor (PI)-based desensitization (DS) in humans has demonstrated variable reduction in HLA antibody levels that is often associated with variable rebound following treatment cessation.The…2017 American Transplant Congress
Emerging Safety and Tolerability of Obinutuzumab, a Type 2 Anti-CD20 Monoclonal Antibody for the Desensitization of Renal Transplant Candidates.
Background: Rituximab has limited efficacy for desensitizing allosensitized patients (pts) with end-stage renal disease (ESRD) and enabling kidney transplantation (KTx), however, tissue B-cell depletion is…2017 American Transplant Congress
Differential Suppressive Effects of Costimulatory Blockade (CD28/B7), Anti-IL6R, Bruton's Tyrosine Kinase and Janus Kinase Inhibition on De Novo vs. Recall Alloantibody Responses: Are Combined Drug Therapy Approaches Desirable?
Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA
Purpose: Preformed and de novo donor specific antibodies (DSA) contribute significantly to demise of allograft functions. There is no approved therapies for prevention or treatment…2017 American Transplant Congress
In Vivo Administration of Plerixafor in Humans Mobilizes Bone Marrow Resident Plasma Cells That Demonstrate Apoptosis in Both Bone Marrow and Peripheral Blood.
1University of Cincinnati, Cincinnati; 2Cincinnati Children's, Cincinnati; 3Duke, Durham
Plasma-cell (PC) targeted therapies can reduce HLA sensitization. However, bone marrow (BM) niche resident plasma cells (BMNRPC) demonstrate resistance to proteasome inhibitor (PI) therapy. Plerixafor…2017 American Transplant Congress
Circulating Donor-Specific Memory B Cells (mBc) Discriminates Kidney Transplant Patients with Histological Lesions of ABMR in Absence of Circulating DSA.
Chronic (c)ABMR is a main cause of immune-mediated kidney allograft loss. For its diagnosis, specific histological lesions together with presence of circulating donor-specific alloantibodies (DSA)…2017 American Transplant Congress
Inhibition of Memory T Cell Alloresponses by TIM-1+ B Cells.
Background:Alloreactive memory T cells mediate accelerated rejection of allografts and prevent tolerance induction. While regulatory B cells (Bregs) can promote tolerance induction through suppression of…2017 American Transplant Congress
Characterization of Human Plasma Cell Proteasome Adaptations to Proteasome Inhibitor Therapy: A Precision Medicine Approach to Overcome Drug Resistance in Desensitization.
1U of Cincinnati, Cincinnati, OH; 2Cincinnati Children's, Cincinnati, OH
Purpose: Bone marrow niche-resident plasma cells (BMNRPCs) exhibit variable sensitivity to proteasome inhibitor (PI) therapy. Here, we characterized alterations in the gene and protein expression…2017 American Transplant Congress
Inflammatory Conditions Dictate the Effect of MSC on B Cell Function.
The immunomodulatory capacity of mesenchymal stem or stromal cells (MSC) makes them a promising therapeutic tool for immune disease and organ transplantation. The effects of…
- « Previous Page
- 1
- …
- 24
- 25
- 26
- 27
- 28
- …
- 35
- Next Page »